Sort   by:  
 Page size 
ProteomicsLC-MS/MS analyses of human PDAC cell lines after treatment with a new SUMO inhibitor
Pancreatic ductal adenocarcinoma (PDAC) still carries a dismal prognosis with overall five-year survival of 8%. Conventional combination chemotherapies are a clear advance in the treatment of PDAC, however subtypes of the disease exist, which exhibit extensive resistance to such therapies. Genomic M...
ORGANISM(S): Homo sapiens (Human) 
2020-01-06 | PXD011347 | Pride
Pancreatic cancer Myc Sumo Lc-ms/ms 
ProteomicsTarget Landscape of Clinical Kinase Inhibitors
Here, we provide a comprehensive overview of the selectivity profiles of 242 kinase inhibitors currently in clinical trials. We screened available inhibitors against human protein kinases by using the Kinobead technology resulting in a drug matrix identifying the druggable kinome and related protein...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2018-01-12 | MSV000081932 | MassIVE
Sort   by:  
 Page size